Aktis Oncology, Inc. (AKTS) vs Cullinan Therapeutics, Inc. (CGEM)
A side-by-side comparison of Aktis Oncology, Inc. and Cullinan Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AKTS
Aktis Oncology, Inc.
$17.84HealthcareDelayed quote: Oct 6, 2026, 3:40 PM EDT
CGEM
Cullinan Therapeutics, Inc.
$16.34HealthcareDelayed quote: Oct 6, 2026, 3:40 PM EDT
Total return — AKTS vs CGEM
growth of $100 · dividends reinvested · last 1yAKTS -17.3% (-17.3%/yr)CGEM +47.2% (+47.2%/yr)CGEM compounded faster over this window
AKTS CGEM
AKTS vs CGEM: by the numbers
- •CGEM is the larger company ($1.00B vs $953M market cap).
- •Both run net losses; CGEM's is the smaller (0.00% vs -727.04% net margin).
Metrics side by side
Valuation
| Metric | AKTS | CGEM |
|---|---|---|
| P/S ratio | 94.71 | N/A |
| P/B ratio | 1.97 | 3.12 |
Profitability
| Metric | AKTS | CGEM |
|---|---|---|
| Gross margin | 100.00% | 0.00% |
| Operating margin | -1149.52% | 0.00% |
| Net margin | -727.04% | 0.00% |
| ROE | -15.09% | -63.62% |
| ROIC | -16.54% | -68.64% |
Growth (annualized)
| Metric | AKTS | CGEM |
|---|---|---|
| Total return CAGR (5Y) | N/A | -7.48% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.